Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED SCHEDULE OF INVESTMENTS (Parenthetical)

v3.23.1
CONSOLIDATED SCHEDULE OF INVESTMENTS (Parenthetical)
$ in Thousands
Mar. 31, 2023
USD ($)
Firm
Dec. 31, 2022
USD ($)
Firm
Investment Holdings [Line Items]    
Investment, Basis Spread, Variable Rate 8.00% 7.50%
Tax basis of investments, gross, unrealized appreciation $ 87,900 $ 72,200
Tax basis of investments, gross, unrealized depreciation 106,600 112,000
Tax basis of investments, unrealized appreciation (depreciation), net 18,700 39,800
Tax basis of investments, cost for income tax purposes 3,100,000 3,000,000
Investment Owned At Cost 3,150,846 3,005,696
Investment Owned At Fair Value $ 3,130,178 $ 2,963,955
1-month LIBOR    
Investment Holdings [Line Items]    
Interest rate 4.86% 4.40%
3-month LIBOR    
Investment Holdings [Line Items]    
Interest rate 5.19% 4.77%
6-month LIBOR    
Investment Holdings [Line Items]    
Interest rate 5.31% 5.14%
1-month SOFR    
Investment Holdings [Line Items]    
Interest rate 4.63%  
3-month SOFR    
Investment Holdings [Line Items]    
Interest rate 4.51%  
6-month SOFR    
Investment Holdings [Line Items]    
Interest rate 4.09%  
Common Stock | Fair Value Inputs Level1 [Member]    
Investment Holdings [Line Items]    
Number of publicly traded companies | Firm 35 43
Warrant | Fair Value Inputs Level1 [Member]    
Investment Holdings [Line Items]    
Number of publicly traded companies | Firm 24 27
Biotechnology Tools    
Investment Holdings [Line Items]    
Investment Owned At Fair Value $ 33,032 $ 32,825
Media/Content/Info    
Investment Holdings [Line Items]    
Investment Owned At Fair Value 9,956 35
Surgical Devices    
Investment Holdings [Line Items]    
Investment Owned At Fair Value 4,189 3,038
Consumer & Business Products    
Investment Holdings [Line Items]    
Investment Owned At Fair Value 2,593 2,821
Communications & Networking    
Investment Holdings [Line Items]    
Investment Owned At Fair Value 107,201 101,833
Drug Delivery    
Investment Holdings [Line Items]    
Investment Owned At Fair Value 23 90
Drug Discovery & Development    
Investment Holdings [Line Items]    
Investment Owned At Fair Value 1,220,057 1,150,707
Medical Devices & Equipment    
Investment Holdings [Line Items]    
Investment Owned At Fair Value 1,155 1,834
Information Services    
Investment Holdings [Line Items]    
Investment Owned At Fair Value 62,039 60,759
Semiconductors    
Investment Holdings [Line Items]    
Investment Owned At Fair Value 966 21,921
Healthcare Services Other    
Investment Holdings [Line Items]    
Investment Owned At Fair Value 214,199 198,763
Manufacturing Technology    
Investment Holdings [Line Items]    
Investment Owned At Fair Value 48,993 46,109
Diversified Financial Services    
Investment Holdings [Line Items]    
Investment Owned At Fair Value 87,805 68,569
Sustainable And Renewable Technology    
Investment Holdings [Line Items]    
Investment Owned At Fair Value 12,899 15,486
Software    
Investment Holdings [Line Items]    
Investment Owned At Fair Value 828,712 798,264
Consumer And Business Services [Member]    
Investment Holdings [Line Items]    
Investment Owned At Fair Value 474,883 439,384
Electronics & Computer Hardware    
Investment Holdings [Line Items]    
Investment Owned At Fair Value 21,476 21,517
Phathom Pharmaceuticals, Inc. | Royalty Contract    
Investment Holdings [Line Items]    
Investment Owned At Cost 4,600 4,600
Investment Owned At Fair Value 3,300 3,400
Black Crow AI, Inc. affiliates | Promissory Notes [Member]    
Investment Holdings [Line Items]    
Investment Owned Balance Principal Amount 2,800 3,000
Senior Secured    
Investment Holdings [Line Items]    
Investment Owned At Fair Value $ 2,910,526 $ 2,741,388